MET and Small-Cell Lung Cancer
AbstractSmall-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC. View Full-Text
Share & Cite This Article
Gelsomino, F.; Rossi, G.; Tiseo, M. MET and Small-Cell Lung Cancer. Cancers 2014, 6, 2100-2115.
Gelsomino F, Rossi G, Tiseo M. MET and Small-Cell Lung Cancer. Cancers. 2014; 6(4):2100-2115.Chicago/Turabian Style
Gelsomino, Francesco; Rossi, Giulio; Tiseo, Marcello. 2014. "MET and Small-Cell Lung Cancer." Cancers 6, no. 4: 2100-2115.